why choose us

First received: July 26, 2023

Clinical Trial: Subcutaneous Abatacept in Renal Transplant Recipients

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Kidney Transplant Recipient

Study Type: INTERVENTIONAL


Official Title: Early Substitution of Subcutaneous Abatacept for Belatacept as Costimulation Blockade to Minimize Calcineurin Inhibitors (CNI) Exposure After Kidney Transplantation

Brief Summary: After a kidney transplant, patients take drugs called anti-rejection drugs (immunosuppressives) to prevent their bodies from rejecting the new kidney.At present it is not possible to have a successful transplant without these drugs.These drugs make it possible for a person who receives the transplant to accept the "foreign" kidney.Most patients who get a transplant need to take anti-rejection medications for the rest of their lives, or for as long as the kidney continues to work.Researchers are looking…

Read more